Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Septerna, Inc.NASDAQ: SEPN
Other Current Assets · Q3 FY2026 · quarter ended Sep 2026
Other current assets rises 2448.8% from a year ago
Other current assets stood at $9.86M at the end of Q3 FY2026, up 2448.8% from a year earlier and up 25.0% from the prior quarter. Over 3 fiscal years it compounded at +78.1% a year.
Context
- Other current assets amounted to 1.6% of total assets at the end of Q3 FY2026, up 1.5 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +2448.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.15M USD
- Year-over-year change
- +476.0%
- 3-year CAGR
- +78.1%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.15M | +476.0% |
| FY2024 | 2024-12-31 | 200K | +117.4% |
| FY2023 | 2023-12-31 | 92K | -54.9% |
| FY2022 | 2022-12-31 | 204K | — |
Other Current Assets vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 other current assets of $9.86M is the 3rd highest of the 7 companies compared; the peer median is $4.94M.
- Its year-over-year change of +2448.8% is the highest of 6, against a peer median of +83.2%.
- Other current assets amounts to 1.6% of total assets for SEPN, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $29.37M | +129.4% | +280.8% | 2.1% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $12.43M | — | — | 1.0% |
SEPNSepterna, Inc. | Sep 2026 | $9.86M | +2448.8% | +78.1% | 1.6% |
| Mar 2026 | $7.4M | +38.7% | +7.8% | 1.8% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $2.48M | +181.6% | +117.2% | 0.5% |
| Mar 2026 | $1.63M | +83.2% | -22.3% | 3.5% | |
| Mar 2026 | $201K | +74.8% | +144.0% | 0.2% | |
| Peer median (excluding SEPN) | $4.94M | +83.2% | +117.2% | 1.4% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.